Search

Trophic interactions play a critical role in regulating ecosystem functioning. Advances in trophic ecology have shifted the focus from characterizing resources based on a single 'currency' such as energy or biomass to more complex multidimensional approaches that consider the resource quality, hence require detailed estimation of different nutrients. For this purpose, ecologists use a wide plethora of extraction and quantification methods that differ substantially in precision and accuracy and vary in efficiency across sample types and taxa. Yet, ecologists seem largely oblivious to these methodological drawbacks and their severe theoretical implications. Focusing on the three main macro‐nutrients groups; proteins, lipids and carbohydrates, we provided an overview of the main extraction and quantification methods and their inherent limitations, and discussed possible consequences for ecology research and theory development. We urge ecologists to adopt a standard method for estimating each macronutrient group or to use multiple methods when feasible, until more accurate and precise chromatographic methods become accessible. We hope that our study will raise awareness to the many shortcomings of macro‐nutrient estimations to assist in strengthening and further developing the important field of trophic ecology. [ABSTRACT FROM AUTHOR]

Objectives: Patients with relapsed/refractory AL amyloidosis (RRAL) have poor prognosis, but emerging data shows promising results with the use daratumumab. We evaluated daratumumab treatment in RRAL in real‐world setting. Methods: A retrospective multisite study of RRAL patients treated with daratumumab alone and in combinations. Results: Forty‐nine patients, diagnosed between 1.1.2008 and 1.2.2018 were included; 27% also had multiple myeloma (MM). Revised Mayo score was ≥ 3 in 67%. Hematologic overall response rate was 81%, 64% achieved very good partial response (VGPR) or better. Concurrent active MM was associated with lower rates of VGPR (OR 0.19, 95% CI 0.04‐0.81; P =.03) in a multi‐variate analysis. Cardiac and renal responses were 74% and 73%, respectively. Median progression‐free survival (PFS) was 28.4 months and median overall survival (OS) was not reached; 2‐year PFS and OS were 68.6 ± 7.5% and 90.4 ± 4.6%, respectively. Hematologic response correlated with prolonged PFS and OS. Daratumumab was safe and well tolerated, no patients discontinued therapy due to toxicity. Our data was aligned with outcomes from a systematic literature review, which identified 10 case series (n = 517) and 2 clinical trials (n = 62) meeting prespecified criteria. Conclusions: Our data support favorable safety tolerability and efficacy of daratumumab among non‐selective RRAL patients in a real‐world setting. [ABSTRACT FROM AUTHOR]